If a change in HER2 status is found to be significantly frequent in gastric cancer, management strategy recommendations similar to those of breast cancer should be introduced for gastric cancer, although it will be important to consider that biopsy from metastases/recurrence or metastasectomy is invasive and burdensome for patients. The gene discussed is ERBB2; the disease is breast carcinoma.